Vunakizumab significantly improved clinical responses in active psoriatic arthritis in a phase 2 trial. Read more about the study.

Two studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate, but these did not select for poor prognosis. The aim, therefore, of the SPEED trial ...

AbbVie ABBV announced positive top-line data from two phase III studies evaluating its psoriasis drug, Skyrizi (risankizumab) for a new indication — active psoriatic arthritis. Skyrizi is presently ...

Tildrakizumab maintained long-term safety in PsA patients through week 208, with adverse events consistent with previous findings and no new safety concerns. Phase 3 studies INSPIRE-1 and INSPIRE-2 ...

Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

A Bristol Myers Squibb drug that was first in its class to hit a certain immunological target now has positive data from two pivotal tests in psoriatic arthritis that could support expanding use of ...

The study showed that that patients with higher disease activity had significantly lower levels of physical activity. Researchers have found that patients with psoriatic arthritis (PsA) show similar ...

Psoriatic arthritis is a heterogeneous inflammatory disorder that affects both women and men, with musculoskeletal symptoms typically occurring at age 40 to 60. Approximately 2-4% of individuals in ...

A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high ...

If you have psoriatic arthritis (PsA), you’re no stranger to joints that hurt or swell, as well as a variety of other symptoms. Both men and women are diagnosed with this autoimmune arthritis in ...